Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3102 (omarigliptin) monotherapy vs placebo in type 2 diabetes mellitus
2012-003626-24Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-3102 monotherapy with Placebo (2 arms). Primary endpoint: HbA1c change from baseline at week 24. Started Nov 2012; status: completed.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-003626-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003626-24.